RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Headache Articles

Article provides an overview of treatment-resistant Migraines. Alternate strategies may be required for overcoming the treatment resistance of certain types of migraines.
Cervicogenic headaches—often misdiagnosed as a sinus headache or ocular disturbances—may be effectively managed by the use of anesthesia to block the occipital nerve branches.
Discussion of triptan options in the treatment of migraines. Reviews available migraine medications.
A case report on the use of a combination sumatriptan and Fioricet protocol in successful first-line treatment of post-dural puncture headache.
Puncturing the dura membrane in a way that leaves a self-sealing flap may entirely eliminate post-procedure spinal fluid leakage that triggers puncture headaches.
The combination of headache and chronic pain in a patient presents challenges to both headache and pain management clinicians due to the lack of overlap between the two specialties.
Modern management modalities are vital to treating headaches effectively.
An overview of the efficacy of several triptan agents in menstrually-related migraine (MM), as well as of other treatment modalities that are commonly used in the treatment of MM.
Extensive experience in evaluating and treating patients with migraines yields observations that can help the pain practitioner grapple with the complexities of migraine patients.
Long-acting opioids can help alleviate the pain associated with severe, refractory chronic daily headaches.
The use of sEMG biofeedback is effective for the treatment of chronic tension headaches. Get tips on how to use this on your patients from a pain management expert.
Sumatriptan 6mg subcutaneous is approved in a variety of countries for the acute treatment of migraine headache. Additionally, it is approved for the acute treatment of cluster headache attacks in the United States as the result of clinical trials. Two studies using subcutaneous sumatriptan 6mg, both reported by Ekbom,1,2 examined the 6mg subcutaneous dose.
The pain of the cluster attack is extreme and starts very quickly, usually without an aura or a warning. Read a discussion of cluster headache prevention in this article.
The involvement of the immune system in chronic headache has been speculated upon since the 1970s. 2,3 Various components of the immune system have been examined in relation to headache. 4,5 While great strides have been made in advancing our understanding of neuroimmunology, the complexities of the system make its specific role in headache pathology unclear.
Memantine has only recently been introduced in the U.S. for dementing disorders, although it has been used in Europe for some time. It blocks N-methyl-D-aspartate (NMDA) glutamate receptors that are thought to be intrinsic to pain transmission, windup, long-term potentiation and central sensitization.
close X
SHOW MAIN MENU
SHOW SUB MENU